Related Experiment Video
Updated: Aug 6, 2026

Facile Preparation of 4-Substituted Quinazoline Derivatives
Published on: February 15, 2016
1-Aryl-6,7-Dimethoxy-3,4-Dihydroisoquinoline-2(1H)-Sulfonamides as hCA XII Selective Inhibitors: Experimental and
Federico Ricci1, Anna Di Fiore2, Andrea Angeli3
1CHIBIOFARAM Department, University of Messina, Messina, Italy.
Abstract:
Human carbonic anhydrase XII (hCA XII) represents an important pharmacological target for different types of cancer. hCA XII plays a crucial role in regulating both extracellular and intracellular pH, thereby influencing cancer cell proliferation, invasion, growth, and metastasis. Although the interaction features of hCA inhibitors (hCAIs) with the catalytic site of distinct hCA isoforms are generally well described, the lack of selectivity remains a major challenge. In a previous work, we have reported a series of 1-aryl-6,7-dimethoxy-3,4-dihydroisoquinoline-2(1H)-sulfonamides displaying weak activity against the ubiquitous hCA I and hCA II, thus emerging as hCAIs that may be free of unwanted side-effects. Herein, further evaluation of their CA inhibitory effects allowed to disclose three potent hCA XII inhibitors at low nanomolar concentrations (Ki values ranging from 5.5 to 6.5 nM). Additionally, they showed remarkable isoform selectivity compared with the well-known inhibitor SLC-0111, currently in clinical trials as an antitumor agent. Crystallography analyses and computational studies clarified the molecular basis of this behavior and provided valuable insights for the rational design of selective inhibitors targeting hCA XII.
Insights
Researchers developed novel carbonic anhydrase inhibitors (hCAIs) targeting human carbonic anhydrase XII (hCA XII), a key player in cancer progression. These potent and selective hCA XII inhibitors offer a promising avenue for developing new cancer therapies with fewer side effects.
Area of Science:
- Biochemistry
- Pharmacology
- Oncology
Background:
- Human carbonic anhydrase XII (hCA XII) is a significant pharmacological target in cancer.
- hCA XII regulates pH, impacting cancer cell proliferation, invasion, growth, and metastasis.
- Developing selective hCA inhibitors (hCAIs) is challenging due to isoform similarity.
Purpose of the Study:
- To evaluate a series of novel 1-aryl-6,7-dimethoxy-3,4-dihydroisoquinoline-2(1H)-sulfonamides for their inhibitory effects on hCA XII.
- To assess the isoform selectivity of these compounds compared to existing inhibitors.
- To elucidate the molecular basis for selective hCA XII inhibition.
Main Methods:
- In vitro enzyme inhibition assays to determine inhibitory constants (Ki).
- Isoform selectivity profiling against various carbonic anhydrase enzymes.
- X-ray crystallography and computational modeling to understand binding interactions.
Main Results:
- Three novel compounds demonstrated potent inhibition of hCA XII at low nanomolar concentrations (Ki 5.5–6.5 nM).
- These compounds exhibited remarkable selectivity for hCA XII over other isoforms, outperforming the clinical candidate SLC-0111.
- Structural analyses revealed key molecular interactions responsible for the observed selectivity.
Conclusions:
- The identified 1-aryl-6,7-dimethoxy-3,4-dihydroisoquinoline-2(1H)-sulfonamides are potent and selective hCA XII inhibitors.
- These findings provide a strong foundation for the rational design of targeted hCA XII-based cancer therapeutics.
- The developed inhibitors offer a promising alternative for cancer treatment with potentially reduced off-target effects.
Related Concept Videos
Inhibitors of Bacterial DNA Synthesis
Amines to Sulfonamides: The Hinsberg Test
Generally, a primary amine reacts with the Hinsberg reagent to produce an N-substituted benzenesulfonamide. The electron-withdrawing sulfonyl...
Stereoisomerism of Cyclic Compounds
Disubstituted Cyclohexanes: cis-trans Isomerism
In cyclohexane, the substituents can occupy different positions generating distinct isomers.
Antifungal Agents
